[Skip to Content]
[Skip to Content Landing]
Views 384
Citations 0
Comment & Response
November 21, 2019

Going Beyond Results of the PEMBRO-RT Trial

Author Affiliations
  • 1Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • 2Department of VIP Medical Services, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
JAMA Oncol. Published online November 21, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.5028

To the Editor The recently published Original Investigation by Theelen and colleagues regarding the PEMBRO-RT trial1 has brought promising and encouraging results for the efficacy and safety of stereotactic body radiotherapy (SBRT) followed by treatment with pembrolizumab compared with treatment with pembrolizumab alone in patients with advanced non–small cell lung cancer (NSCLC) that progressed after at least 1 regimen of chemotherapy, though the primary end point was not reached. However, in addition to the perspectives and limitations mentioned by the authors, several other issues deserve attention.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×